Focus: CathWorks is a publicly-traded medical device company specializing in AI-powered catheter guidance for cardiovascular interventions, headquartered in Newport Beach, CA. The company focuses on non-invasive coronary artery disease assessment and percutaneous coronary intervention guidance.
Profile data last refreshed 1h ago · AI intelligence enriched 2w ago
Strong acquisition outcome by a medtech leader offers career stability and scale, but limited current headcount needs and integration uncertainty require careful timing.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for CathWorks
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from CathWorks's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
8-K Filing: Medtronic plc (MDT) (CIK 0001613103) — EX-99.1
EX-99.1
Medtronic Completes Acquisition of CathWorks to Strengthen Cardiovascular Diagnostics Portfolio - Digital Health News
Medtronic Completes Acquisition of CathWorks to Strengthen Cardiovascular Diagnostics Portfolio Digital Health News
Medtronic Completes $585M Acquisition of CathWorks - Medical Product Outsourcing
Medtronic Completes $585M Acquisition of CathWorks Medical Product Outsourcing
Medtronic completes acquisition of CathWorks, expanding its leadership in transforming care for patients with cardiovascular disease - PR Newswire
Medtronic completes acquisition of CathWorks, expanding its leadership in transforming care for patients with cardiovascular disease PR Newswire
Wire-free artery assessment tech joins Medtronic in $585M deal - Stock Titan
Wire-free artery assessment tech joins Medtronic in $585M deal Stock Titan
Imaging-Based FFR on Par With Wire for PCI Outcomes - MedPage Today
Imaging-Based FFR on Par With Wire for PCI Outcomes MedPage Today
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
FFRangio-guided versus pressure wire-guided PCI: design and rationale of the multicentre, randomised ALL-RISE trial.
Angiogram based fractional flow reserve in patients with dual/triple vessel coronary artery disease.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo